Clinical Trial Update: Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating Zanzalintinib in combination with immuno-oncology agents in patients with various solid tumors; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Non-clear Cell Renal Cell Carcinoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: Exelixis | Conditions: Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | Status: RECRUITING